Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesDermatologyAmbetter Nevada Onychomycosis Testing Coverage | O…
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy N/A

    Onychomycosis testing (microscopy/peroxidase, fungal culture, NAAT/PCR)

    Customize your policy alerts

    Sign up for all Ambetter Nevada policy alerts

    Know when Ambetter Nevada releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria for laboratory testing methods (microscopy/peroxidase, fungal culture, and molecular NAAT/PCR) for diagnosis of onychomycosis in the outpatient setting; intended for providers and medical reviewers of Ambetter Nevada plans.

    Policy Summary
    PayerAmbetter Nevada
    PolicyOnychomycosis testing (microscopy/peroxidase, fungal culture, NAAT/PCR)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument signs/symptoms of onychomycosis and that test results will influence clinical management.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3test categories addressed
    KOHpreferred method
    Not supportedNAAT/PCR stance
    Includedcoding examples
    3reminder sections
    Centenepolicy owner

    Coverage Criteria for Onychomycosis Testing

    Microscopy/Peroxidase Tests

    Microscopy/peroxidase tests are considered medically necessary when ALL of the following are met:

    Microscopy/peroxidase medical necessity: A. Member shows signs or symptoms of onychomycosis (e.g., nails that are discolored, deformed, brittle, and/or foul‑smelling; subungual debris; separation of the nail from the nail bed).
    Microscopy/peroxidase medical necessity: B. Results of testing would influence the member's clinical management.

    KOH preparation with direct microscopy is cited in guidance as the preferred, rapid, and cost‑effective diagnostic method; testing is not supported for other indications.

    Fungal Culture

    Fungal culture is considered medically necessary when ALL of the following are met:

    Fungal culture medical necessity: A. Member shows signs or symptoms of onychomycosis (e.g., nails that are discolored, deformed, brittle, and/or foul‑smelling; subungual debris; separation of the nail from the nail bed).
    Fungal culture medical necessity: B. Results of testing would influence the member's clinical management.

    Current evidence does not support fungal culture for other indications.

    NAAT/PCR (Culture-Independent Molecular Tests)

    Culture-independent molecular tests (NAAT/PCR):

    NAAT/PCR stance: Current evidence does not support culture-independent molecular tests (NAAT/PCR) for onychomycosis for all indications.

    PCR may detect nonviable or nonpathogenic organisms, which can limit its clinical utility; KOH/microscopy and culture remain the traditional diagnostic approaches.

    Current evidence supports use of laboratory testing to confirm suspected onychomycosis only when results will affect management. Microscopy/KOH preparation or peroxidase-stained microscopy and fungal culture are considered medically necessary when the member shows signs or symptoms of onychomycosis (for example: nails that are discolored, deformed, brittle, foul‑smelling; subungual debris; or nail separation from the nail bed) and when test results would influence clinical management. Culture-independent molecular tests (NAAT/PCR) are limited by the evidence and are not supported for all indications; PCR may detect nonviable or nonpathogenic organisms and therefore has interpretive limitations compared with microscopy and culture.

    Coverage of diagnostic testing described in this policy is subject to the Health Plan’s applicable terms, conditions, exclusions and limitations. This clinical policy is a guide to medical necessity to assist in coverage determinations and administering benefits; it does not constitute a guarantee of payment. Providers must follow state and federal requirements and applicable Health Plan administrative policies when requesting or submitting claims for these tests.

    Culture-independent molecular tests (NAAT/PCR) for onychomycosis are not supported for all indications based on current evidence. The policy notes that although PCR can increase detection rates, it may detect dead or nonpathogenic fungal material, which can limit its clinical usefulness for definitive diagnosis and routine use.

    Coding and Billing Examples

    Microscopy/Peroxidase and Fungal Culture CPT codesCPTCovered
    87206Direct microscopy, fungal
    87220Stain, peroxidase or other for fungus (if matching document mapping)
    87101Culture, fungal, routine
    87102Culture, fungal, other
    87106Identification, fungal
    87107Identification, fungal (additional)
    87143Culture, dermatophyte
    87149Isolate identification (fungal)
    Culture-independent molecular (NAAT/PCR) CPT codesCPT
    87481Infectious agent detection by nucleic acid (NAAT), multiple organisms; Nail-ID (Vikor Scientific) example noted
    87500Infectious agent detection by nucleic acid (NAAT), other
    87641Infectious agent detection by nucleic acid (NAAT), Trichophyton and related
    87652Infectious agent detection by nucleic acid
    87653Infectious agent detection by nucleic acid
    87798Infectious agent detection by molecular method, other
    Culture-independent molecular (NAAT/PCR) CPT codesCPT
    87481Infectious agent detection by nucleic acid (NAAT), multiple organisms; Nail-ID (Vikor Scientific) example noted
    87500Infectious agent detection by nucleic acid (NAAT), other
    87641Infectious agent detection by nucleic acid (NAAT), Trichophyton and related
    87652Infectious agent detection by nucleic acid
    87653Infectious agent detection by nucleic acid
    87798Infectious agent detection by molecular method, other

    Provider Responsibilities and Required Documentation

    Note

    Coding is informational only

    CPT and diagnostic codes listed in this clinical policy are provided for informational purposes only; their inclusion does not guarantee coverage or represent exhaustive coding guidance. Providers should reference current CPT manuals and professional coding resources before claim submission.

    Prior Authorization

    Prior authorization governed by plan documents

    This clinical policy is a guide to medical necessity used to assist in coverage decisions and benefit administration; any prior authorization requirements are governed by the Health Plan's administrative procedures and coverage documents.

    Step Therapy

    No step therapy specified in this policy

    Background

    Onychomycosis (nail fungus) commonly presents with nail discoloration, deformation or hypertrophy, brittleness or crumbling, subungual debris, separation from the nail bed, and sometimes a foul odor. Laboratory confirmation is recommended prior to treatment to distinguish fungal infection from nonfungal nail disorders and to guide appropriate therapy. This policy addresses outpatient diagnostic testing modalities — primarily KOH preparation with direct microscopy (preferred, rapid, and cost‑effective), fungal culture, and culture‑independent molecular tests (NAAT/PCR) — and limits use of each test to situations where clinical signs/symptoms are present and results will influence management.

    Definitions and Clinical Signs

    Onychomycosis — Key signs, indications, and testing notes
    Common signs/symptomsNails that are discolored, deformed, brittle, and/or foul-smelling; subungual debris; separation of the nail from the nail bed.
    When microscopy/peroxidase is medically necessaryMember shows signs/symptoms of onychomycosis AND results of testing would influence clinical management.
    When fungal culture is medically necessaryMember shows signs/symptoms of onychomycosis AND results of testing would influence clinical management (presumptive and/or definitive culture).
    Preferred initial diagnostic methodPotassium hydroxide (KOH) preparation with direct microscopy is preferred: highly specific, rapid, and cost‑effective; KOH alone may be sufficient to initiate treatment.
    Limitations of molecular testingCurrent evidence does not support culture‑independent molecular tests (NAAT/PCR) for all indications; PCR may detect nonviable or nonpathogenic organisms (guidance note).
    Policy Summary
    PayerAmbetter Nevada
    PolicyOnychomycosis testing (microscopy/peroxidase, fungal culture, NAAT/PCR)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument signs/symptoms of onychomycosis and that test results will influence clinical management.
    SourceLink
    On This Page
    Coverage Criteria for Onychomycosis TestingCoding and Billing ExamplesProvider Responsibilities and Required DocumentationBackgroundDefinitions and Clinical Signs

    The policy does not specify any step therapy requirements for onychomycosis testing; it focuses on appropriate indications for testing (signs/symptoms and whether results will influence management).

    Prior Authorization

    Order tests only for appropriate indications

    Ensure testing is ordered only when the member demonstrates signs or symptoms of onychomycosis and when test results will influence clinical management; tests ordered for other indications may not be supported.

    Documentation Required

    Required clinical documentation

    Document the presence of signs or symptoms of onychomycosis (examples include nails that are discolored, deformed, brittle, and/or foul-smelling; subungual debris; separation of the nail from the nail bed) and the clinical rationale that test results will influence management.

    • Record specific signs/symptoms observed (e.g., subungual debris, nail separation).
    • Document how test results are expected to change treatment or management decisions.
    Documentation Required

    Provider responsibilities and documentation

    Providers must follow applicable state and federal requirements and Health Plan administrative policies; they are expected to exercise professional medical judgment and remain responsible for documentation supporting medical necessity.

    Denial Risk

    Denial risk if indication or management rationale missing

    Tests may be denied when used for indications other than evaluation of signs/symptoms of onychomycosis or when results would not influence clinical management.

    • Microscopy/peroxidase tests, fungal culture, and NAAT/PCR are supported only when signs/symptoms are present and results will affect management.
    • NAAT/PCR is not supported for all indications based on current evidence.
    Denial Risk

    Coverage subject to plan terms and exclusions

    Coverage decisions and the administration of benefits remain subject to all terms, conditions, exclusions, and limitations of the member's coverage documents (e.g., evidence of coverage, certificate of coverage, policy or contract).